In the initial randomized discontinuation trial, the frequency of drug discontinuation due to toxicities was 16%.
The dates of treatment initiation and discontinuation, initial dosing, dates and reasons for treatment interruptions and treatment changes, dosing modifications, and follow-up tumor assessments were also recorded.
Other treatment-related data collected included dates of treatment initiation and discontinuation, initial dosing, dates and reasons of treatment interruptions and treatment changes, dosing modifications and follow-up tumor assessments.
Initial treatment was discontinuation or decrease in FK-506.
Adverse effects included grade 2 suppression of bone marrow function, hair loss, and GI symptoms such as diarrhea, and vomiting that were tolerable and managed by reducing administration dose to 80% of the initial dosage without discontinuation of the chemotherapy.
Patients who restarted their initial medication after discontinuation, as defined above, were also considered non-persistent patients.
As a follow-up to the above, Table 1 uses some results from the tapentadol ER trials (e.g. "initial 3 months discontinuation" [ 3 ]) but the data presented in the table are mixed with inappropriate assumptions (utility measures are the same as for tramadol).
This study aimed to further determine the impact of brief daytime periods of NREM sleep on 'offline' (task discontinuation after initial training) and 'on-task' (performance within the test session) changes in motor skill performance (finger tapping task).
Participants were followed until the earliest of the following: first suicidal thoughts, discontinuation of initial ART regimen, death, loss to care (>12 months with no HIV appointments), or administrative censoring (2014-2015).
